Bone Marrow TransplantationNCT00005556
Retention of Bone Marrow Donors in a National Registry
An observational study of Bone Marrow Transplantation and Blood Disease, run by National Heart, Lung, and Blood Institute (NHLBI).
Trial summary
To identify factors that affected the National Marrow Donor Program's (NMDP) success in retention of bone marrow volunteers. Read more about this study
- Who is it for?
- Ages Up to 100 years, men only
- Conditions the study is for
- Bone Marrow Transplantation, Blood Disease
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- May 1997to Apr 2003
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 100 years
- Men only
- No healthy volunteers
- Child, Adult, Older adult
No eligibility criteria
About this study
To identify factors that affected the National Marrow Donor Program's (NMDP) success in retention of bone marrow volunteers.
Read the detailed description
BACKGROUND:
As bone marrow transplantation becomes one of the preferred treatments for life-threatening diseases of the blood, increasing numbers of patients must seek compatible marrow from unrelated donors. The low probability of finding a good patient-donor marrow match means that between one- to two-thirds of ill patients never locate a donor with perfectly compatible marrow. Furthermore, once volunteers are identified as a preliminary match for a patient, 30 to 40 percent are either unwilling or medically unable to actually donate marrow. Thus, volunteer attrition contributes significantly to the problems already inherent in finding a suitable donor candidate.
DESIGN NARRATIVE:
The study examined the relationship of volunteer characteristics and donor center factors to volunteer psychological outcomes during two critical stages in the blood testing process and to donor center rates of volunteer cooperation at these stages.
Longitudinal and cross-sectional survey data were gathered from a total of over 2,900 potential marrow donors who were at one of two critical decision points in the process leading to donation (DR-blood-typing, CT-blood-typing), and from personnel at the 100 NMDP donor centers. These data allowed the investigators to (a) describe the distribution and interrelationships between donor center structural characteristics and the strategies centers utilize for volunteer recruitment and retention, (b) determine which donor center factors (both structural and tactical) and volunteer background characteristics best predict positive volunteer-specific psychological outcomes at later typing stages, and examine and revise models of individual volunteer-specific outcomes and aggregate across-center retention rates.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
- Conditions
- Bone Marrow Transplantation, Blood Disease
- Medical subject headings
- Hematologic Diseases
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2000 (estimated)
- Study startMay 1997
- Study completionApr 2003
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Bone Marrow TransplantationStudies of the same condition, open and under way.
- More trials run by National Heart, Lung, and Blood Institute (NHLBI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Investigators
- Galen Switzer, University of Pittsburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00005556
- Sponsor's protocol ID
- 5101
- Other IDs
- R29HL056901
- Status last verified
- Aug 2004
- First submitted
- 25 May 2000
- Last updated
- 13 May 2016
- Results posted
- No
Publications
Dew MA, Switzer GE, DiMartini AF, Matukaitis J, Fitzgerald MG, Kormos RL. Psychosocial assessments and outcomes in organ transplantation. Prog Transplant. 2000 Dec;10(4):239-59; quiz 260-1. doi: 10.1177/152692480001000408.
PubMed 11232552Switzer GE, Dew MA, Goycoolea JM, Myaskovsky L, Abress L, Confer DL. Attrition of potential bone marrow donors at two key decision points leading to donation. Transplantation. 2004 May 27;77(10):1529-34. doi: 10.1097/01.tp.0000122219.35928.d6.
PubMed 15239616Myaskovsky L, Switzer GE, Dew MA, Goycoolea JM, Confer DL, Abress L. The association of donor center characteristics with attrition from the national marrow donor registry. Transplantation. 2004 Mar 27;77(6):874-80. doi: 10.1097/01.tp.0000116394.88804.a7.
PubMed 15077030
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retention of Bone Marrow Donors in a National Registry
- ClinicalTrials.gov ID
- NCT00005556
- Acronym / sponsor ID
- 5101
- Conditions
- Bone Marrow Transplantation, Blood Disease
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)US National Institutes of Health
- Study start
- May 1997
- Study completion
- Apr 2003 (actual)
- First posted
- 26 May 2000 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To identify factors that affected the National Marrow Donor Program's (NMDP) success in retention of bone marrow volunteers.
Detailed description
BACKGROUND:
As bone marrow transplantation becomes one of the preferred treatments for life-threatening diseases of the blood, increasing numbers of patients must seek compatible marrow from unrelated donors. The low probability of finding a good patient-donor marrow match means that between one- to two-thirds of ill patients never locate a donor with perfectly compatible marrow. Furthermore, once volunteers are identified as a preliminary match for a patient, 30 to 40 percent are either unwilling or medically unable to actually donate marrow. Thus, volunteer attrition contributes significantly to the problems already inherent in finding a suitable donor candidate.
DESIGN NARRATIVE:
The study examined the relationship of volunteer characteristics and donor center factors to volunteer psychological outcomes during two critical stages in the blood testing process and to donor center rates of volunteer cooperation at these stages.
Longitudinal and cross-sectional survey data were gathered from a total of over 2,900 potential marrow donors who were at one of two critical decision points in the process leading to donation (DR-blood-typing, CT-blood-typing), and from personnel at the 100 NMDP donor centers. These data allowed the investigators to (a) describe the distribution and interrelationships between donor center structural characteristics and the strategies centers utilize for volunteer recruitment and retention, (b) determine which donor center factors (both structural and tactical) and volunteer background characteristics best predict positive volunteer-specific psychological outcomes at later typing stages, and examine and revise models of individual volunteer-specific outcomes and aggregate across-center retention rates.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Study design
Who may qualify
- Ages
- Up to 100 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2016.
- Background: PubMed 11232552Dew MA, Switzer GE, DiMartini AF, Matukaitis J, Fitzgerald MG, Kormos RL. Psychosocial assessments and outcomes in organ transplantation. Prog Transplant. 2000 Dec;10(4):239-59; quiz 260-1. doi: 10.1177/152692480001000408.
- Background: PubMed 15239616Switzer GE, Dew MA, Goycoolea JM, Myaskovsky L, Abress L, Confer DL. Attrition of potential bone marrow donors at two key decision points leading to donation. Transplantation. 2004 May 27;77(10):1529-34. doi: 10.1097/01.tp.0000122219.35928.d6.
- Background: PubMed 15077030Myaskovsky L, Switzer GE, Dew MA, Goycoolea JM, Confer DL, Abress L. The association of donor center characteristics with attrition from the national marrow donor registry. Transplantation. 2004 Mar 27;77(6):874-80. doi: 10.1097/01.tp.0000116394.88804.a7.
Related trials for Bone Marrow Transplantation
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingObservational study
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Leukemia, Lymphoma
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
RecruitingPhase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Galen Switzer
University of Pittsburgh
Questions about this trial
What is this clinical trial studying?
An observational study of Bone Marrow Transplantation and Blood Disease, run by National Heart, Lung, and Blood Institute (NHLBI).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 May 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00005556, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2016.